C. Marcela Díaz‐Montero

Author

Also Known As

C Diaz-Montero, C Marcela Diaz-Montero, C Marcela Díaz-Montero, C. Diaz-Montero, C. M. Diaz-Montero, C. Marcela Diaz-Montero, C. Marcela Diaz‐Montero, C. Marcela Díaz-Montero, C. Marcela Díaz-Montero, C. Marcela Díaz‐Montero

200

Publications

4.8K

Citations

H-Index

Concepts

All Affiliations

Cleveland Clinic Medical University of South Carolina Cleveland Clinic Lerner College of Medicine The University of Texas MD Anderson Cancer Center Tanta University

About

C. Marcela Díaz‐Montero is an author at Cleveland Clinic specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	20	2.3K
2	Immunology	11	11	1.7K
3	Cell Biology	8	8	665
4	Health Sciences	2	2	134
5	Allergy	1	1	78

C. Marcela Díaz‐Montero

Publications

3.7K

Citations

H-Index

Page 1

	Year	Citations
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy C. Marcela Díaz‐Montero, Mohamed L. Salem, Michael I. Nishimura, Cancer Immunology Immunotherapy Clinical Cancer StageTumor BiologyMedicineMetronomic TherapyImmunology	2008	1.2K
A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells Samantha Solito, Erika Falisi, C. Marcela Díaz‐Montero, Blood	2011	329
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis Anil K. Sood, Guillermo N. Armaiz-Peña, Jyotsnabaran Halder, Journal of Clinical Investigation Chronic StressAdrenergic ModulationFocal Adhesion KinaseSignaling PathwayReceptor Tyrosine Kinase	2010	271
Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α Yana G. Najjar, Patricia Rayman, Xuefei Jia, Clinical Cancer Research	2016	185
Recovery from Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses In Vivo When Stimulated with the TLR3 Agonist Poly(I:C) Mohamed L. Salem, C. Marcela Díaz‐Montero, Amir A. Al-Khami, The Journal of Immunology	2009	114
Increased incidence of venous thromboembolism with cancer immunotherapy Joanna Roopkumar, Shadi Swaidani, Ann S. Kim, Med ThrombosisPulmonary EmbolismVenous ThrombosisMedicineHematology	2021	110
Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer Alberto J. Montero, C. Marcela Díaz‐Montero, Yehuda E. Deutsch, Breast Cancer Research and Treatment Breast OncologyOncologyMedicinePathologyNeoadjuvant Treatment	2011	107
Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series Lillian Sun, Pauline Funchain, Jung Min Song, Journal for ImmunoTherapy of Cancer	2018	104
PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation C. Marcela Díaz‐Montero, James N. Wygant, Bradley W. McIntyre European Journal of Cancer Cancer ResearchSignal TransductionSignaling PathwayMedicineReceptor Tyrosine Kinase	2006	99
A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients Chuan Li, Yee Peng Phoon, Keaton Karlinsey, The Journal of Experimental Medicine	2021	98

Page 1